Search
Cadmium
go.drugbank.com/drugs/DB14085ExperimentalIt is a metal and ingestion will lead to CADMIUM POISONING.
Lifirafenib
go.drugbank.com/drugs/DB14773InvestigationalLifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).
Balovaptan
go.drugbank.com/drugs/DB14823InvestigationalBalovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)).
Categories: Antidiuretic Hormone Receptor AntagonistsIFx-Hu2.0
go.drugbank.com/drugs/DB18396InvestigationalIt is composed of plasmid DNA encoding the streptococcal membrane protein, Emm55, contained within a cationic polymer.
NDX-3315
go.drugbank.com/drugs/DB18671InvestigationalNDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled [heparin].
Sutetinib
go.drugbank.com/drugs/DB18841InvestigationalSutetinib is under investigation in clinical trial NCT05168566 (Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer).
Synonyms: (2e)-n-(3-cyano-7-ethoxy-4-((3-ethynylphenyl)amino)-6-quinolinyl)-4-(dimethylamino)-2-butenamide, 2-butenamide, n-(3-cyano-7-ethoxy-4-((3-ethynylphenyl)amino)-6-quinolinyl)-4-(dimethylamino)-, (2e)-Palazestrant
go.drugbank.com/drugs/DB18971InvestigationalStandard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer).
IP-2018
go.drugbank.com/drugs/DB19049InvestigationalIP-2018 is under investigation in clinical trial NCT04686916 (Clinical Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients).
AG0302-COVID19
go.drugbank.com/drugs/DB16435InvestigationalSponsored by Anges, Inc. in Japan, the AG0302-COVID19 is a DNA-based vaccine that recently completed Phase I/II trials (NCT04527081)[A226813, L30548].
OS2966
go.drugbank.com/drugs/DB17207InvestigationalOS2966 is a humanized integrin β1 (CD29) blocking antibody currently evaluated for the treatment of acute myeloid leukemia, glioblastoma and ovarian cancer.[A254561, L47351]